INO-8875, a potent and highly selective Adenosine-1 agonist, is in Phase 2 clinical development for glaucoma. The candidate has completed a Phase 1/2 trial in patients, in which INO-8875 was administered topically to the eye. Treatment with INO-8875 was well tolerated and resulted in a statistically significant reduction in intraocular pressure (IOP). INO-8875 is currently being evaluated in a multiple-dose Phase 2 trial. For a more detailed description of the trial protocol, please visit clinicaltrials.gov.
Preclinical studies in multiple different animal models with INO-8875 have demonstrated a consistent IOP-lowering effect. The compound appears to work primarily by increasing the outflow of ocular fluid (aqueous humor) via the trabecular meshwork pathway, the main pathway used by healthy eyes to maintain normal IOP. As a new mechanism of action, INO-8875 may provide significant benefit to glaucoma patients.